As shown in Fig. 1, mutations that cause loss of function in LDLR or APOB or gain of function in PCSK9 result in an individual moving from a low point in the population cholesterol distribution to being over the diagnostic cut-off for FH (7.5 mmol/l). Here, LDLR is linked to familial hyperaldosteronism.